Jukka Westermarck and his group received the Elias Tillandz -prize
Prof. Jukka Westermarck and his group received the Elias Tillandz -prize for the best publication of the year for his ground-breaking study on that reveals the druggability of type-2A phosphatase, which has been largely regarded as a non-druggable cancer target. Link to study.
Warmest congratulations to the whole team!
Read more:
Recent Posts
- New Funding for our Centre’s Researchers Warm congratulations to all for their funding! Cancer Foundation Finland Project grants Travel grants The Read moreDecember 12, 2025
- Sami Ventelä and Jukka Westermarck recognized by Medical Association Duodecim for their influential work. Medical association Duodecim selects each year persons that have been most influential in the field Read moreDecember 11, 2025
- Our affiliated Group Leader Rafa Najumudeen secures ERC Consolidator Grant The European Research Council (ERC) has awarded a Consolidator Grant to our affiliated Group Leader, Read moreDecember 9, 2025
- New computational tool helps scientists interpret complex single-cell data Researchers from Laura Elo’s group, have developed a new computational method to interpret complex single-cell Read moreNovember 17, 2025
- Carlos Rogério Figueiredo received the Young Investigator Award Carlos Rogério Figueiredo has received the Young Investigator Award from the Scandinavian Society for Immunology. Read moreNovember 4, 2025
- Participate to Open Hardware Workshop, sign up now! Access to research hardware remains a global challenge and it impacts also researchers in high-income Read moreNovember 3, 2025